Promising combo for tough hodgkin lymphoma cases

NCT ID NCT03016871

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested a new treatment plan for people with Hodgkin lymphoma that returned or didn't respond to initial therapy. The approach combines an immunotherapy drug (nivolumab) with standard chemotherapy (ICE) to shrink the cancer before a stem cell transplant. The goal was to see how well this combination works and what side effects it causes. The study included 78 adults who had already tried at least one treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary โ€” we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REFRACTORY HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington, 98109, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Yale University

    New Haven, Connecticut, 06520, United States